HOUSTON, TX, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on September 9, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin’s game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. CEO Mark White will detail the Company’s growing body of clinical evidence, including collaborations with leading in ...

Core Insights - Nexalin Technology, Inc. has appointed Justin Van Fleet as Chief Financial Officer effective August 1, 2025, bringing over 20 years of experience in public accounting and assurance services [1][2] - Mr. Van Fleet has a strong track record in financial systems development, regulatory compliance, and strategic financial management, particularly in guiding companies through complex financial transactions [2][3] - The company is at a pivotal moment with its innovative neurostimulation technology aimed at treating serious mental health conditions, and Mr. Van Fleet's expertise will be crucial for scaling operations and advancing the technology [4] Company Overview - Nexalin Technology designs and develops non-invasive neurostimulation products to address the global mental health epidemic, utilizing bioelectronic medical technology [6] - The company's Generation 2 and Generation 3 devices are currently under FDA review and are designed to provide deep-brain stimulation without drugs or invasive procedures, targeting conditions such as anxiety and depression [4][6] - Nexalin's Gen-2 15 milliamp neurostimulation device has received approval in China, Brazil, and Oman, indicating its potential for international market expansion [6]

Core Insights - Nexalin Technology, Inc. is hosting a webinar on June 3, 2025, to discuss its innovative approach to mental healthcare using its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology [1][2] - The company is positioned in a $537 billion mental health market, with international regulatory approvals and U.S. expansion plans underway [2] - Nexalin's technology includes real-time AI-driven patient monitoring and aims to provide scalable, at-home treatment options [2] Company Overview - Nexalin designs and develops non-invasive neurostimulation products aimed at addressing the global mental health epidemic [4] - The company's devices are believed to penetrate deep brain structures associated with mental health disorders, enhancing patient response without adverse side effects [4] - The Nexalin Gen-2 15 milliamp neurostimulation device has received approval in China, Brazil, and Oman [4]

Core Viewpoint - Nexalin Technology, Inc. has successfully closed a public offering of 3,850,000 shares at a price of $1.30 per share, raising approximately $5.0 million in gross proceeds before expenses [1]. Company Overview - Nexalin Technology, Inc. specializes in developing innovative neurostimulation products aimed at addressing the global mental health crisis. The company's products are designed to be non-invasive and are believed to provide relief for mental health issues [5]. - The company utilizes bioelectronic medical technology to treat mental health disorders, with a focus on penetrating deep brain structures associated with these conditions. Nexalin's next-generation devices are expected to enhance patient response without adverse side effects [5]. - The Nexalin Gen-2 15 milliamp neurostimulation device has received approval in China, Brazil, and Oman [5]. Offering Details - The public offering was conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) on April 23, 2025, and declared effective on April 29, 2025 [3]. - Maxim Group LLC served as the sole book-running manager for the offering [2].

Company Overview - Nexalin Technology, Inc. is a leader in Deep Intracranial Frequency Stimulation (DIFS™) technology aimed at addressing mental health issues through innovative neurostimulation products [5] - The company's products are designed to be non-invasive and are believed to provide relief for individuals suffering from mental health disorders [5] Public Offering Details - Nexalin announced a public offering of 3,850,000 shares of common stock priced at $1.30 per share, with expected gross proceeds of approximately $5.0 million [1] - The offering is set to close on or about May 6, 2025, subject to customary closing conditions [1] - An additional 577,500 shares may be purchased by underwriters within a 45-day option period at the public offering price [1] Use of Proceeds - The net proceeds from the offering will be utilized for working capital and general corporate purposes, including sales and marketing, product development, and capital expenditures [2] Regulatory Compliance - A shelf registration statement for the shares was filed with the SEC on April 23, 2025, and was declared effective on April 29, 2025 [3] - The offering is being conducted through a written prospectus and prospectus supplement available on the SEC's website [3]

Core Viewpoint - Nexalin Technology, Inc. is initiating formal regulatory engagement with the FDA for its Gen-2 SYNC system, aimed at treating Alzheimer's disease, dementia, and mild cognitive impairment (MCI) [1][2]. Regulatory Engagement - The company plans to submit a Q-Submission ("Q-Sub") to the FDA to facilitate structured dialogue regarding clinical trial design [1][2]. - This decision follows recent publications, encouraging internal data, and preliminary feedback from the FDA, marking a critical step in advancing Gen-2 SYNC as a non-invasive therapeutic option [2]. Product Development - The Gen-2 SYNC system features technical enhancements over prior generations, including a redesigned enclosure and a proprietary 15 milliamp advanced waveform [3]. - The company is rebranding the device to clearly differentiate it from earlier versions, marketing it as "Gen-2 SYNC" [3]. Company Focus - Nexalin is committed to progressing regulatory engagement and advancing its neuromodulation platform as a promising therapeutic alternative for cognitive and neuropsychiatric disorders [3]. - The company designs and develops innovative neurostimulation products aimed at addressing the global mental health epidemic, utilizing bioelectronic medical technology [5].

Company Overview - Nexalin Technology, Inc. is focused on developing innovative neurostimulation products aimed at addressing the global mental health epidemic, utilizing non-invasive bioelectronic medical technology [4] - The company's neurostimulation devices are designed to penetrate deep brain structures associated with mental health disorders, potentially enhancing patient response without adverse side effects [4] Upcoming Event - Nexalin will host a webinar on April 3, 2025, at 4:15 p.m. ET, featuring CEO Mark White, who will discuss the company's clinical data and advancements in its Gen-3 HALO™ Clarity & Virtual Clinic model [2][3] - The webinar will include a live Q&A session, allowing investors to engage directly with the CEO [2] Market Potential - Nexalin's solutions have demonstrated clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries, which affect millions and have limited effective treatments [2] - The mental health market is projected to reach $537 billion by 2030, indicating substantial growth potential for Nexalin's products [2]